TY - JOUR
T1 - Identifying pathways to the prevention of dementia
T2 - the Netherlands consortium of dementia cohorts
AU - Oomens, Julie E.
AU - Moonen, Justine E. F.
AU - Vos, Stephanie J. B.
AU - Beran, Magdalena
AU - Mateus, Pedro
AU - De Deyn, Peter P.
AU - van der Flier, Wiesje M.
AU - Geerlings, Mirjam I.
AU - Huisman, Martijn A.
AU - Ikram, M. Arfan
AU - Schram, Miranda T.
AU - Slagboom, P. Eline
AU - Verschuren, W. M. Monique
AU - Beekman, Marian
AU - Bermejo, Inigo
AU - Birhanu, Mahlet
AU - Bron, Esther E.
AU - Dekker, Andre
AU - Frentz, Ingeborg
AU - Garst, Swier J. F.
AU - Jaarsma, Eva
AU - Kok, Almar A. L.
AU - Marcolini, Sofia
AU - Mei, Leon
AU - van Charante, Eric P. Moll
AU - Richard, Edo
AU - Schalkwijk, Casper G.
AU - van Sloten, Thomas T.
AU - Teunissen, Charlotte E.
AU - Twait, Emma L.
AU - Verberk, Inge M. W.
AU - Vonk, Jet M. J.
AU - van de Waarenburg, Marjo P. H.
AU - Wolters, Frank J.
AU - Jansen, Willemijn J.
AU - Visser, Pieter Jelle
PY - 2025/2/12
Y1 - 2025/2/12
N2 - BackgroundAggregation of cohort data increases precision for studying neurodegenerative disease pathways, but efforts to combine data and expertise are often hampered by infrastructural, ethical and legal considerations. We aimed to unite various cohort studies in the Netherlands to enhance research infrastructure and facilitate research on dementia etiology and its public health implications.MethodsThe Netherlands Consortium of Dementia Cohorts (NCDC) includes participants with initially no established cognitive impairment from 9 Dutch cohorts: the Amsterdam Dementia Cohort (ADC), Doetinchem Cohort Study (DCS), European Medical Information Framework for Alzheimer's Disease (EMIF-AD), Longitudinal Aging Study Amsterdam (LASA), the Leiden Longevity Study (LLS), The Maastricht Study, the Memolife substudy of the Lifelines cohort, Rotterdam Study and Second Manifestations of ARTerial disease-Magnetic Resonance (SMART-MR) study. The objectives of NCDC are to improve data infrastructure and access to cohorts related to aging and dementia, investigate the role of Alzheimer's disease and vascular pathology in the development of dementia and estimate the public health impact of established dementia risk factors by assessing their relative contribution to the population burden of dementia.ResultsWe increased the findability, accessibility, interoperability and reusability (FAIR) status of the cohorts through harmonization of data across cohorts, implementation of medical imaging repositories for scan management, implementation of the Personal Health Train infrastructure and provision of meta-data in existing cohort catalogues. We established the ethical and legal frameworks required for federated and pooled analyses and performed the first remote federated data analyses using the Personal Health Train infrastructure. To determine biomarkers of Alzheimer's disease, endothelial dysfunction and inflammation, 2554 plasma samples were analyzed centrally. Federated, pooled, and coordinated meta-analyses have led to multiple publications in the context of NCDC.ConclusionThe combination of population-based and clinical cohorts, the coordinated assessment of plasma markers in previously collected samples and implementation and use of the Personal Health Train infrastructure for federated analysis are both feasible and promising for future collaborative efforts.
AB - BackgroundAggregation of cohort data increases precision for studying neurodegenerative disease pathways, but efforts to combine data and expertise are often hampered by infrastructural, ethical and legal considerations. We aimed to unite various cohort studies in the Netherlands to enhance research infrastructure and facilitate research on dementia etiology and its public health implications.MethodsThe Netherlands Consortium of Dementia Cohorts (NCDC) includes participants with initially no established cognitive impairment from 9 Dutch cohorts: the Amsterdam Dementia Cohort (ADC), Doetinchem Cohort Study (DCS), European Medical Information Framework for Alzheimer's Disease (EMIF-AD), Longitudinal Aging Study Amsterdam (LASA), the Leiden Longevity Study (LLS), The Maastricht Study, the Memolife substudy of the Lifelines cohort, Rotterdam Study and Second Manifestations of ARTerial disease-Magnetic Resonance (SMART-MR) study. The objectives of NCDC are to improve data infrastructure and access to cohorts related to aging and dementia, investigate the role of Alzheimer's disease and vascular pathology in the development of dementia and estimate the public health impact of established dementia risk factors by assessing their relative contribution to the population burden of dementia.ResultsWe increased the findability, accessibility, interoperability and reusability (FAIR) status of the cohorts through harmonization of data across cohorts, implementation of medical imaging repositories for scan management, implementation of the Personal Health Train infrastructure and provision of meta-data in existing cohort catalogues. We established the ethical and legal frameworks required for federated and pooled analyses and performed the first remote federated data analyses using the Personal Health Train infrastructure. To determine biomarkers of Alzheimer's disease, endothelial dysfunction and inflammation, 2554 plasma samples were analyzed centrally. Federated, pooled, and coordinated meta-analyses have led to multiple publications in the context of NCDC.ConclusionThe combination of population-based and clinical cohorts, the coordinated assessment of plasma markers in previously collected samples and implementation and use of the Personal Health Train infrastructure for federated analysis are both feasible and promising for future collaborative efforts.
KW - Netherlands Consortium of Dementia Cohorts
KW - Personal Health Train
KW - FAIR
KW - Data infrastructure
KW - Data access
KW - Harmonization
KW - Alzheimer's disease
KW - Vascular pathology
KW - Dementia prevention
KW - Cohort studies
KW - PROFILE
KW - HEALTH
KW - UPDATE
U2 - 10.1186/s12883-024-03995-4
DO - 10.1186/s12883-024-03995-4
M3 - Article
SN - 1471-2377
VL - 25
JO - BMC Neurology
JF - BMC Neurology
IS - 1
M1 - 59
ER -